Otsuka looks to maximise growth before Abilify watershed
This article was originally published in Scrip
Otsuka Holdings has unveiled its first mid-term business plan since going public in a $2.4 billion IPO in Japan late last year, under which it is looking to raise net sales of pharmaceuticals (including nutrition solutions) to ¥847.0 billion ($10.47 billion) in the fiscal year to 31 March 2014, up from ¥721.4 billion last fiscal year.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.